Now we are waiting for the FDA to approve the drug.

[fdastock]

So you know the biotech market is hot right now especially after VNDA’s 900% gain overnight. People are now trying to find the next hidden gem biotech stock that will multiply your investment.

In the biotech world, FDA decisions can be a gamble but statistics are on your side. 70%-90% of all drugs in Phase 3 testing receive FDA approval. The reason why so many drugs are approved at that point is because most the unsuccessful ones are weeded out in the Phase 1, 2, and 3 trials.

To help you find the next big biotech stock waiting for FDA approval, we are for a limited time giving away a FREE FDA Calendar to the next 1,000 new forum members of the FavStock.com stock forums.

Don’t worry the forum is completely free and the FREE FDA Calendar is actually free, that mean no credit card, no fine print, no games, no BS. This is on a first come first serve biases. Stop by FavStocks.com and get your FREE FDA Calendar now!

http://www.favstocks.com/forum/fda-calendar/

http://www.favstocks.com/forum/



If you’re interested in the following stocks your probably interested in the calendar;
Nephros, Inc. (OTC:NEPH)
BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
Amgen, Inc. (NASDAQ:AMGN)
Gilead Sciences, Inc. (NASDAQ:GILD)
Celgene Corporation (NASDAQ:CELG)
Geron Corporation (NASDAQ:GERN)

####

About FavStocks.Com

FavStocks.Com is a news portal and forum covering the news and financial sector. It may feature its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars.

For more investment news, go to FavStocks.com. Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. FavStocks.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

I may be lucky to be one of the 1000

[arif940]

Aradigm Corp. one of the specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company’s programs under development include ARD-3100 (Liposomal ciprofloxacin), ARD-3150 (Liposomal ciprofloxacin), ARD-1100 (Liposomal ciprofloxacin) and ARD-1600 (Nicotine). Its collaborative programs under development include ARD-1550 (Inhaled treprostinil), ARD-1500 (Inhaled liposomal treprostinil) and ARD-1700 (combination products).
On 16th July,2009 Zogenix, Inc. was granted approval of the Sumavel™ DosePro™ (sumatriptan injection) needle-free delivery system which enables subcutaneous delivery of sumatriptan without a needle for the treatment of acute migraine. Aradigm is entitled to a $4 million milestone payment upon first commercial sale, and royalty payments upon any sales of products in the U.S. and other countries, including the European Union, which may be developed and sold using the DosePro technology. The company share holders saw a gain of 10% on this approval for a short time. ARDM also highly recommended by Reuters stock analyst but for some strange reason this stock is ignored by investors.
Is that because the royalty payments are not good enough? or people are still waiting for some investors recommendations which I guess eventually will be there at higher cost.

[Venu]

I am new to this forum as well as to Stocks, I am doing some study on this BIO stocks from 2 months and I bought this stock BDSI after getting the approval and it is down hill. Any one knows what happened to this stock and when will it rise.

[jonjon]

Got into ARDM this week, not much happening right now. I guess I'll wait it out.

[rjfoodman]

I am not convinced on ardm. Maybe I am missing something. Can anyone fill me in??

[Wam34]

OfficialWire: Why Does This Stock Continue To Drop After Great News? (ARDM, HEB, BDSI)

[ins0mniak]

Pardon my noobocity, but didn't GERN already have it's banger? Even with a new development their market cap is the same. Unless they are expecting a quick rise and return after the approval.

[rb1]

I am in ADLS still. Does anyone know if it will go down any more, or should I just hold on to it until it goes for approval again?

[rjfoodman]

Hey rb1, not really watching this today. I am just holding.

MESA FAZ, ERY has shot up. RST, AEZS dropped and maybe a buy.

GL

Cheers,...RJ

[ravoyi]

Thanks, Is BIOEMED REPORTS good? Any one used those accounts